Navigation Links
Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip
Date:1/1/2014

spine, total hip and femoral neck regions (all p<0.001). The largest increases were observed with the romosozumab 210 mg once-monthly dose, with mean increases compared with baseline of 11.3 percent at the lumbar spine, 4.1 percent at the total hip and 3.7 percent at the femoral neck.

Additionally, in exploratory analyses, BMD gains were significantly greater than active comparators at month 12, with romosozumab treatment achieving a mean increase of 11.3 percent at the lumbar spine compared to increases of 4.1 percent and 7.1 percent at the same region achieved with FOSAMAX and FORTEO, respectively. At the total hip, romosozumab treatment increased BMD 4.1 percent, while observed gains with FOSAMAX were 1.9 percent and with FORTEO were 1.3 percent (all p<0.001).1

The comparators to romosozumab were placebo, oral FOSAMAX (70 mg weekly) and subcutaneous FORTEO (20 μg daily), both of which were open-label.1 

Adverse events were similar across groups, except for mild, generally non-recurring injection site reactions observed more frequently with romosozumab compared to placebo, but with no observed dose-related relationship. Most common adverse events included mild upper respiratory tract infection, pain in the back and joints, and headache. These reactions did not lead to study drug discontinuation or study withdrawal; the safety of romosozumab will be further addressed in subsequent larger studies.1

"There remains a significant need for additional treatment options that form new bone. Romosozumab is designed to stimulate bone formation, which makes it different from most available treatments that reduce bone resorption," said Prof. Dr. Iris Loew-Friedrich, chief medical officer, UCB. "We are encouraged by the emerging efficacy and safety profile, and look forward to further investigating its potential in the ongoing global Phase 3 clinical program
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. NW Bios International Phase III GBM Brain Trial Is Subject Of BBC TV Report In The UK
2. Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
3. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
4. ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study
5. BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
6. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
7. BioSpecifics Technologies Corp. Announces Initiation of Phase 2b Trial of CCH for Treatment of Frozen Shoulder Syndrome
8. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
9. AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data at Anesthesia Medical Conference
10. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2b Frozen Shoulder Syndrome Study of Collagenase Clostridium Histolyticum
11. Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2015 BGI a annoncé aujourd,hui que ... l,ADN situé à Hong Kong ... of Pathologists  (Collège des pathologistes américains, ou CAP). ... Kong constituent le premier laboratoire clinique ... certification du CAP en Chine, car il satisfait ...
(Date:7/2/2015)... , July 2, 2015  New product launches ... its leading role in educating thought leaders about new ... can heavily influence how well a new therapy performs ... study from research and consulting leader Best Practices, LLC, ... need to focus on are early stage thought leader ...
(Date:7/2/2015)... YORK , July 2, 2015 ... a conspicuously high-growth market segment in hematology testing, ... publisher said that Roche,s recent unveiling of its Bloodhound ... the cobas m 511 hematology analyzer ... only capture growth enjoyed by current leader CellaVision, ...
Breaking Medicine Technology:BGI obtient la certification du Collège des pathologistes américains (CAP) 2Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3
(Date:7/3/2015)... Lewisville, TX (PRWEB) , ... July 03, 2015 , ... ... in the United States, named Mariah N. Manzanares, MD as the new Medical Director ... the new facility medical director of our Frisco facility,” said Dr. James M. Muzzarelli, ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is ... opening is the first sweetFrog store located in Mississippi. The premium frozen yogurt chain ... 2014. , The store, located at 104 Railroad Avenue, New Albany, MS 38652, will ...
(Date:7/2/2015)... ... July 02, 2015 , ... When Walker Parking ... the University of Minnesota, they knew it would save the university energy and ... award-winning choice: the total energy savings after installation was an impressive 89 percent, ...
(Date:7/2/2015)... , ... July 02, 2015 , ... As Americans celebrate ... the hot temps, skin cancer is on the rise. July is UV Safety Month, ... raising awareness about the importance of getting skin checks. Experts say most skin cancers ...
(Date:7/2/2015)... ... July 02, 2015 , ... ActiveBunch.com recently launched as a social network ... to function as a lifestyle community, Active Bunch allows users to connect with like-minded ... and participate in discussions or group events. , The spokesperson for Active Bunch ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:sweetfrog Opens First Location in Mississippi 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:Local Physicians Warn of Holiday Health Hazards 2Health News:Local Physicians Warn of Holiday Health Hazards 3Health News:Local Physicians Warn of Holiday Health Hazards 4Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2
... Jan. 12 Just because you are traveling or,on holiday ... good health habits.,In fact, it is an easier time to ... ) , Many Americans take to ... -- be it business or pleasure, and they often fall ...
... developers summit for companies interested in integrating NurseTesting ... ... (Vocus) January 12, 2009 -- Analysts and industry-watchers believe ... but also the entire nature of the business models that ...
... Medical Equipment the 17th fastest growing business in Louisville, Business First ... , ... (Vocus) January 12, 2009 -- DRE, Inc., a premier international ... of Louisville as a 2008 Company of the Year. The award caps ...
... open enrollment helps Medicare recipients make sure they,ve made the ... ... (Vocus) January 12, 2009 -- Although annual Medicare enrollment has ... during the current Medicare open enrollment period. That information comes ...
... Sweden The Swedish investment,company Karolinska Development AB has ... stem cell and other tissue engineering based,treatments for veterinary ... 2007 EvoStem Finland Oy introduced its first product TendoStem(R),which ... and ligament injuries,in horses. TendoStem(R) is currently on the ...
... Inc., a drug development company focusing on serious Central ... that it held an initial closing of $2.9 million ... will use the funds for the clinical development of ... slowing down disease progression and improving memory and cognition ...
Cached Medicine News:Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Traveling is a Time to be Even Healthier 2Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Traveling is a Time to be Even Healthier 3Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Traveling is a Time to be Even Healthier 4Health News:NurseTesting 2.0 Goes to the Clouds and Invites Developers to Summit 2Health News:NurseTesting 2.0 Goes to the Clouds and Invites Developers to Summit 3Health News:Business First Selects DRE Medical Equipment as a Company of the Year 2Health News:Business First Selects DRE Medical Equipment as a Company of the Year 3Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 2Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 3Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 4Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 5Health News:Karolinska Development Invests in EvoStem Finland Oy 2Health News:New Venture Funding for Alzheimer's Disease Drug Developer 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: